[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroparesis-due-to-diabetes-mellitus-type-i\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroparesis-due-to-diabetes-mellitus-type-i":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100504322","gastroparesis-registry-4-100504322",false,"NCT05846802","Gastroparesis Registry 4","Gastroparesis Registry 4 (GpR4): Improving the Understanding of Gastroparesis and Functional Dyspepsia","GpR4","Inclusion Criteria:\n\n* Age at least 18 years at initial screening visit\n* Symptoms of Gp and\u002For FD of at least 12-weeks duration with varying degrees of nausea, vomiting, early satiety, postprandial fullness, abdominal pain, abdominal burning. Thus, patients can enter the GpR4 registry primarily with abdominal pain suggesting FD-Epigastric Pain Syndrome.\n* Successful completion of gastric emptying scintigraphy of solids using the 4-hour Egg Beaters® protocol (or equivalent generic liquid egg white meal) within the last 9 months\n* Negative upper endoscopy or upper radiographic GI series within 5 years of registration\n\nExclusion Criteria:\n\n* Use of narcotic analgesics greater than three days per week\n* Presence of other conditions that could explain the patient's symptoms such as:\n* Pyloric or intestinal obstruction as evidenced by EGD, UGI, or Abdominal CT\n* Active inflammatory bowel disease\n* Known eosinophilic gastroenteritis or eosinophilic esophagitis\n* Primary neurological conditions that can cause nausea and vomiting such as increased intracranial pressure, space occupying or inflammatory\u002Finfectious lesions\n* Acute or chronic renal failure (serum creatinine \\>3 mg\u002FdL) and\u002For on hemodialysis or peritoneal dialysis\n* Acute liver failure or advanced liver disease (Child's B or C; a Child-Pugh-Turcotte (CPT) score of ≥7)\n* Pancreatic disorder if present on pancreatic imaging or pancreatic function testing\n* Prior gastric surgery including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy, or any fundoplication (Nissen, Tor)\n* Any other condition, which in the opinion of the investigator, could explain the symptoms or interfere with study requirements\n* Females who are pregnant. A urine pregnancy test is routinely obtained on all females immediately prior to gastric emptying procedures.\n* Inability to comply with or complete the gastric emptying scintigraphy test (including allergy to eggs)\n* Inability to obtain informed consent","ALL","18 Years","85 Years",{"count":21,"type":22},250,"ESTIMATED","OBSERVATIONAL","The Gastroparesis Registry 4 (GpR4) is an observational study of patients with symptoms of gastroparesis (Gp) and functional dyspepsia (FD) with either delayed or normal gastric emptying. To better understand these disorders, this registry will capture demographic, clinical, physiological, questionnaire, and patient outcome data to characterize the patients and their clinical course. Participants will complete several questionnaires, complete a nutrient drink test and have a gastric emptying study.",[26,27,28,29,30,31],"Gastroparesis","Gastroparesis Nondiabetic","Gastroparesis Due to Diabetes Mellitus Type I","Gastroparesis Due to Diabetes Mellitus Type II","Functional Disorder of Gastrointestinal Tract","Gastro-Intestinal Disorder","RECRUITING","2026-03-30",{"date":35,"type":36},"2026-04-03","ACTUAL",{"date":38,"type":36},"2024-09-20",{"date":40,"type":22},"2027-04-30",{"name":42,"class":43},"Johns Hopkins Bloomberg School of Public Health","OTHER",6,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100615079","to-study-the-efficacy-and-safety-of-medtronic-780g-insulin-pump-in-people-with-gastroparesis-and-type-1-diabetes-100615079","NCT07287943","To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.","Efficacy and Safety of Medtronic 780G Automated Insulin Delivery System in Adults With Type 1 Diabetes and Gastroparesis","Inclusion criteria\n\n* Age ≥18 years\n* Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months\n* HbA1c ≥8.0%\n* Diagnosis of gastroparesis per National Institute of Health (NIH) definition\n* Willing to use Medtronic 780G system either with Simplera CGM.\n* Ability to provide informed consent before any trial-related activities\n* If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study\n\nExclusion criteria\n\n* Age \\\u003C18 years\n* Current use of inhaled insulin (Afrezza)\n* Patients with T1D using any glucose lowering medications other than insulin at the time of screening\n* Pregnancy, breast feeding, or wanting to become pregnant\n* Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (\\>4 weeks continuously), during the study period\n* History of gastric outlet obstruction or other gastrointestinal structural abnormalities\n* Estimated glomerular filtration rate (eGFR) \\\u003C30 or on dialysis\n* History of SH in the previous 3 months\n* History of two or more episodes DKA requiring hospitalization in the past 12 months\n* Any medical (such as severe cardiovascular disease, malignancy, chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators\n* Use of investigational drugs within 5 half-lives prior to screening\n* Current use of cannabis or history of cannabinoid hyperemesis syndrome",{"count":53,"type":22},34,"INTERVENTIONAL",[56],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.",[59,28],"Type 1 Diabetes",[61,62],"type 1 diabetes","gastroparesis","2026-02-14",{"date":65,"type":36},"2026-02-18",{"date":67,"type":36},"2026-02-09",{"date":69,"type":22},"2026-12-01",{"name":71,"class":43},"Viral N. Shah",1]